Latest On Travere Therapeutics, Inc (RTRX):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2020-11-17 18:33 EST | News | Retrophin rebrands itself as Travere Therapeutics | N/A |  |
| 2020-11-09 13:17 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-09 05:04 EST | Analyst Rating | The Analyst Target Price has increased from $30.75 to $31.38. | Buy | |
| 2020-11-08 13:41 EST | News | Retrophin's (RTRX) CEO Eric Dube on Q3 2020 Results - Earnings Call Transcript | N/A | |
| 2020-11-08 00:47 EST | Financials | Company financials have been released. | Neutral | |
About Travere Therapeutics, Inc (RTRX):
Retrophin, Inc., a biopharmaceutical company, focuses on the identification, development, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of cystinuria. The company's product candidates also consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy. It read more...has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences, NGLY1.org, and Alagille Syndrome Alliance for identification of potential small molecule therapeutics for NGLY1 deficiency and Alagille syndrome. Retrophin, Inc. was founded in 2011 and is headquartered in San Diego, California.
General
- Name Travere Therapeutics, Inc
- Symbol RTRX
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 221
- Last Split Factor1:9
- Last Split Date2011-11-08
- Fiscal Year EndDecember
- IPO Date2012-11-08
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryBiotechnology
- Web URLhttp://www.retrophin.com
Valuation
- Price/Sales (Trailing 12 Mt.) 5.55
- Price/Book (Most Recent Quarter) 4.01
- Enterprise Value Revenue 4.98
Financials
- Most Recent Quarter 2020-09-30
- Current Year EPS Estimate -$1.54
- Next Year EPS Estimate -$2.07
- Next Quarter EPS Estimate -$0.59
- Profit Margin -40%
- Operating Margin -36%
- Return on Assets -7%
- Return on Equity -29%
- Revenue 194.02 million
- Earnings Per Share -$3.42
- Revenue Per Share $4.27
- Gross Profit 170.1 million
- Quarterly Earnings Growth 15.2%
Highlights
- Market Capitalization 1.24 billion
- EBITDA -76322000
- PEG Ratio -1.05
- Analyst Target Price $31.38
- Book Value Per Share $5.91
Share Statistics
- Shares Outstanding 51.05 million
- Shares Float 42.53 million
- % Held by Insiders 90%
- % Held by Institutions 104.8%
- Shares Short 4.81 million
- Shares Short Prior Month 4.73 million
- Short Ratio 18.1
- Short % of Float 10%
- Short % of Shares Outstanding 9%
Technicals
- Beta 0.72
- 52 Week High $25.5
- 52 Week Low $8.98
- 50 Day Moving Average 21.38
- 200 Day Moving Average 19.02
Dividends
- Dividend Date N/A
- ExDividend Date N/A
Travere Therapeutics, Inc (RTRX) Dividend Calendar:
Travere Therapeutics, Inc (RTRX) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
Travere Therapeutics, Inc (RTRX) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Travere Therapeutics, Inc (RTRX) Chart:
Travere Therapeutics, Inc (RTRX) News:
Below you will find a list of latest news for Travere Therapeutics, Inc (RTRX) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Travere Therapeutics, Inc (RTRX) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Travere Therapeutics, Inc (RTRX) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | View |
|---|---|---|
| 2020-11-06 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-11-05 | 8-K (Current report) | |
| 2020-11-05 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-10-22 | 8-K (Current report) | |
| 2020-10-06 | 8-K (Current report) | |
| 2020-10-05 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-09-29 | UPLOAD (SEC-generated letter) | |
| 2020-09-23 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-09-23 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-09-23 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-09-23 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-09-22 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-09-22 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-09-22 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-09-22 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-09-22 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-09-21 | CORRESP (Correspondence) | |
| 2020-09-04 | UPLOAD (SEC-generated letter) | |
| 2020-08-06 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-07-31 | S-8 (Securities to be offered to employees in employee benefit plans) | |
Travere Therapeutics, Inc (RTRX) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Travere Therapeutics, Inc (RTRX). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 90%
Institutional Ownership: 10480%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-11-06 | STEVE ASELAGE | Director | Sell | 20,625.00 | 23.00 | 474,375.00 | 213,107.00 | |
| 2020-11-05 | STEVE ASELAGE | Director | Sell | 2,500.00 | 21.26 | 53,150.00 | 233,732.00 | |
| 2020-10-05 | Peter Heerma | Chief Commercial Officer | Sell | 2,188.00 | 19.35 | 42,337.80 | 42,329.00 | |
| 2020-10-02 | Peter Heerma | Chief Commercial Officer | Sell | 2,188.00 | 18.90 | 41,353.20 | 44,517.00 | |
| 2020-09-23 | Laura Clague | Chief Financial Officer | Sell | 1,500.00 | 18.48 | 27,720.00 | 19,473.00 | |
| 2020-09-23 | WILLIAM E. ROTE | Senior Vice President, R&D | Sell | 1,500.00 | 18.48 | 27,720.00 | 24,086.00 | |
| 2020-09-23 | ELIZABETH E REED | SVP, GC & Corporate Secretary | Sell | 1,500.00 | 18.48 | 27,720.00 | 25,431.00 | |
| 2020-09-23 | Noah L. Rosenberg | Chief Medical Officer | Sell | 750.00 | 18.48 | 13,860.00 | 27,555.00 | |
| 2020-09-22 | Laura Clague | Chief Financial Officer | Sell | 1,500.00 | 18.59 | 27,885.00 | 20,973.00 | |
| 2020-09-22 | WILLIAM E. ROTE | Senior Vice President, R&D | Sell | 1,500.00 | 18.59 | 27,885.00 | 25,586.00 | |
| 2020-09-22 | ELIZABETH E REED | SVP, GC & Corporate Secretary | Sell | 1,500.00 | 18.59 | 27,885.00 | 26,931.00 | |
| 2020-09-22 | Noah L. Rosenberg | Chief Medical Officer | Sell | 750.00 | 18.59 | 13,942.50 | 28,305.00 | |
| 2020-09-21 | Eric M Dube | Chief Executive Officer | Sell | 1,565.00 | 19.29 | 30,186.03 | 94,695.00 | |
| 2020-09-21 | Eric M Dube | Chief Executive Officer | Sell | 9,240.00 | 19.28 | 178,133.34 | 96,260.00 | |
| 2020-09-18 | Eric M Dube | Chief Executive Officer | Buy | 25,000.00 | 102,500.00 | | ||
| 2020-09-18 | Eric M Dube | Chief Executive Officer | Buy | 3,000.00 | 105,500.00 | | ||
| 2020-09-18 | Laura Clague | Chief Financial Officer | Buy | 3,000.00 | 22,473.00 | | ||
| 2020-09-18 | WILLIAM E. ROTE | Senior Vice President, R&D | Buy | 3,000.00 | 27,086.00 | | ||
| 2020-09-18 | ELIZABETH E REED | SVP, GC & Corporate Secretary | Buy | 3,000.00 | 28,431.00 | | ||
| 2020-09-18 | Noah L. Rosenberg | Chief Medical Officer | Buy | 3,000.00 | 29,055.00 | |